Table 4 Characteristics of randomised controlled trials underlying recommendations for treating acute exacerbations of chronic obstructive pulmonary disease with antibiotics
Author, year of Publication | No. of patients (m/f) | % Of patients included of those initially screened | Cardiovascular co-morbidities in exclusion criteria | Average baseline lung function (FEV1 % predicted, FEV1 in litre or PEF litre/min) of study patients at the time of inclusion | Study setting (hospital or outpatient) |
|---|---|---|---|---|---|
Anthonisen et al.25 | 173 (134/39) | — | Yes | 33.9% | O |
Seemungal et al.26 | 83 (59/24) | — | Yes | 41.3% | O |
Patel et al.27 | 29 (21/8) | No | 38.7% | O | |
Nouira et al.28 | 93 (84/9) | 44% | No | 0.7 l | H |
Trials from the Cochrane review 4 | |||||
Berry et al.29 | 53 (31/21) a | NA | NA | NA | O |
Fear et al.30 | 62 (NA) | NA | No | NA | O |
Elmes et al.31 | 74 (47/27) | 76% | Yes | 79.2 l/min | H |
Pines et al.32 | 186 (186/0) | No | 76.0 l/min | H | |
Pines et al.33 | 259 (259/0) | NA | No | 146.0 l/min | H |
Manresa et al.34 | 19 (NA) | NA | No | 172.0 l/min | H |
Jørgensen et al.35 | 270 (115/278) | 97% | Yes | 295.0 l/min (circa) | O |
Sachs et al.36 | 71 (30/41) | NA | No | 63 l/min | O |
Brusse-Keizer37 | 35 (21/14) | 56% | No | 48.6% | O |
Daniels et al.38 | 223 (133/90) | 70% | No | 45.4% | H |
Llor et al.39 | 310 (251/59) | 88% | No | 65.0% | O |
